American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 13, 2025
Earnings Call Speaker Segments
Kirin Smith
executiveThanks, Operator, and thanks to all of you for being with us today. Earlier this morning, before the market opened, AMS put out its earnings press release for the third quarter of 2025. Should you want a copy, you can find it on the company's website, www.aschs.com, listed under press releases within the investors tab. Before I hand things over to management, I want to offer a few comments regarding forward-looking statements. Please be aware that a number of remarks that might be made during this conference call regarding the company's future expectations, plans, and prospects qualify as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, owing to a range of important factors, among them those covered in the company's filings with the SEC. That includes the company's quarterly report on Form 10-Q covering the three-month period that ended June 30, 2025, along with the annual report on Form 10-K for the year that ended December 31, 2024. The company undertakes no obligation to update the information contained in this conference call. Before I pass the call to management, I want to remind everybody about our Q&A policy, under which each participant gets the opportunity to ask one question plus one follow-up. As always, we're glad to address further questions offline whenever you like. With that said, I'd now like to hand the call over to Ray Stachowiak, Executive Chairman. Ray, please go ahead.
Ray Stachowiak
executiveThanks a lot, Kieran, and good afternoon to all of you. We appreciate you being with us for the conference call on our Third Quarter 2025 earnings. I'll start things off with a few opening comments, and after that I'll pass it to Gary Delanous, who serves as our CEO, to share more specifics, and then Scott Frech, our CFO, will take you through a financial review covering our Third Quarter and the first nine months of 2025 results. Once our prepared remarks are done, we'll take questions on the call. I'm glad to share that revenue for the Third Quarter and the nine months of 2025 went up, respectively, mostly because of higher revenue from direct patient care services as the new physicians we brought on in Rhode Island begin ramping up our values. I'm also pleased that we keep achieving better margins and that we stay disciplined and concentrated on operational efficiencies; we keep seeing gains from our shift away from a focus on medical equipment leasing toward a service model that is more patient-centric. It's good to see that our diversified model is delivering obvious advantages, and we're looking forward to the rest of 2025 and to 2026. Our attention stays on creating long-term shareholder value and on extending our historical pattern of consecutive years of substantial revenue growth along with improved margins. Like many small growth businesses, we'll have ordinary fluctuations from quarter to quarter, but across the medium to longer term, we're positioned to carry on our long-term track record. As we keep executing our strategic initiatives and upcoming milestones, I believe our long-term investors will benefit positively. We've charted a path toward long-term outperformance as we carry out our growth strategy and strive to build substantial shareholder value. Now I'll turn the call over to Gary and Scott, who will guide you through our overall business, the quarterly and year-to-date financial results, and our business development pipeline, which offers exciting strategic growth opportunities. With that, Gary, please go ahead.
Gary Delanois
executiveThank you, Ray, and good afternoon to all of you. This marks an exciting moment for the company, and I feel very enthusiastic about the growth opportunities we have both near term and longer term. Our strategy for growing the business is strong, and I'm excited as we keep carrying out our business plan. During this past quarter, revenue grew 2.5% compared with the same period a year earlier, and revenues for the year to date are 5.6% higher than they were at this point last year. I'm happy to report that we experienced substantial growth at our new radiation therapy treatment center in Puebla, Mexico, which delivered 263% annual revenue growth. It was also wonderful to witness an increase of nearly 17% year over year in Gamma Knife revenue. Our ongoing shift away from equipment leasing toward direct patient care services deserves special mention, as revenue from direct patient care services accounted for 56% of our total revenue in the third quarter. I'm also delighted to report that our gross margins rose by almost 16%, and our operating loss narrowed, improving 92%, as we stay committed to operational efficiencies. While we keep pursuing initiatives to grow revenue, we likewise stay focused on enhancing profitability. Adjusted EBITDA for the third quarter of 2025 reached $1.9 million, versus $1.3 million in the third quarter of '24 — a 42% gain. We continue to be diligent about managing our costs and are ready for growth as treatment volumes, especially in Rhode Island, keep rising; we keep seizing operating efficiencies and expanding the business, and although we do anticipate ongoing quarterly gains in treatment volumes, I'm energized by the growth we've observed across the overall business and by the business development initiatives we currently have underway. I'm also enthusiastic about the advantages stemming from our purchase of the three Rhode Island cancer treatment centers and our newer center in Puebla, Mexico. At the Rhode Island centers, our new radiation oncologists are conducting new patient consultations across our three centers, where volumes have bounced back to historical levels, and we anticipate further growth in the fourth quarter. Putting the right team in place is an essential ingredient for expanding our market share to fuel future growth. I stay confident that we will witness steady growth in treatment volumes through continued physician engagement with the healthcare community and especially with our health system joint venture partners, Care New England and Prospect Charter Care. We also stay focused on further optimizing our equipment leasing segment by collaborating closely with our health system customers to build greater community awareness among referring physicians, thereby driving higher utilization of their gamma knife systems, which is regarded as the gold standard for stereotactic radiosurgery. Our international business segment offers yet another significant growth opportunity where we anticipate continued momentum. We hold the only gamma knife centers in Peru and Ecuador. Our third international site is in Puebla, Mexico, and there we’re delivering care to cancer patients across a complete spectrum of cancer diagnoses, using the most sophisticated radiation therapy treatment options that exist in our catchment area. We’re also pleased about launching our fourth international center — a gamma knife facility in Guadalajara, Mexico — and we anticipate beginning patient treatment and bringing in revenue there during the second quarter of 2026. In a nation of 130 million people, this will be the sole S3 gamma knife, and it delivers a significant advantage to patients in Mexico while also plainly serving as an untapped growth engine for us. Looking ahead over the months and years, we anticipate stronger international growth driven by additional treatment volume in Ecuador, robust volume from our recently upgraded center in Peru, and our two new centers in Guadalajara and Puebla, Mexico. Beyond our three existing radiation therapy treatment centers — which were our first direct patient care cancer treatment centers in the U.S. — we keep expanding our footprint in Rhode Island. As we’ve talked about, we received a certificate of need, or CON, allowing us to build and run a fourth radiation therapy center in Bristol, Rhode Island, and permitting there is in progress. Also, this past December we officially secured a CON to build and operate Rhode Island’s first proton beam radiation therapy center, and we’re advancing on locking down land and kicking off the permitting process. For the company, these two new facilities amount to major growth opportunities, and we’re eager to share further updates as they move forward. To wrap up, our confidence in the overall business plan is very high. We’re set up to withstand short-term swings, and we stay concentrated on ongoing operations and new business developments. I have tremendous confidence in the strategies we’ve put in place, our management team, and the potential for long-term growth. Finally, our strong record of long-term revenue growth and better margins, along with our balance sheet, gives me great confidence that we’ll achieve these initiatives in the years ahead. With that, I’ll hand the call to Scott Frech, our CFO, for a financial review.
Scott Frech
executiveThanks, Gary, and good afternoon, everyone. I'll start with a review of our third-quarter performance, then cover the results for the nine months year to date, and afterward we'll open it up for your questions in the Q&A. During the quarter that ended September 30, 2025, total revenue increased 2.5%, coming in at $7.2 million, compared with $7 million in the third quarter of 2024. Inside that third quarter of 2025, revenue from our direct patient services segment was up 9.4%, hitting $4 million, against the same quarter of 2024. Growth there was driven largely by more procedures performed at the new facility in Puebla, Mexico, which we opened last year. Though the base is small, revenue jumped 263%. Clearly, that's a fantastic start, and it demonstrates how substantial the growth from these centers can be. Medical equipment leasing segment revenue declined to $3.1 million from $3.3 million in the third quarter of 2024, reflecting reduced proton beam radiation therapy, or PBRT, volumes. Gamma knife revenue increased 16% versus the prior-year period, reaching 2.1 million in the third quarter of 2025, and gamma knife procedures came to 231 during that quarter, up from 218 in the third quarter of 2024. PBRT revenue climbed to 2.1 million in the third quarter of 2025, a 10.8% improvement over the second quarter of 2025. Proton therapy fractions totaled 1,150 in the third quarter of 2025, which is an 8.1% decrease from the third quarter of 2024. That decline was primarily the result of the normal cyclical fluctuations. Linear accelerator, or Linac, revenue was 15.9% above the second quarter of 2025, at 2.9 million for the third quarter of 2025, and rose 51.2% over the third quarter of 2024, helped by commencing operations in Puebla, Mexico, and by a full complement of radiation oncologists at our Rhode Island locations. Gross margins for the third quarter of 2025 improved to 22.1%, with a year-over-year increase of 60% to 1.6 million, driven mostly by higher treatment volumes. Operating income for the third quarter of 2025 improved dramatically, coming in at a loss of $344,000, versus a loss of $889,000 in the third quarter of 2024. Net losses attributable to American Shared Hospital Services for the third quarter of 2025 improved considerably, at $55,000, or 0 cents per diluted share, compared with a net loss of $207,000, or 3 cents per share, in the third quarter of 2024. Adjusted EBITDA, our non-GAAP financial measure, rose 41% to 1.9 million for the third quarter of 2025, compared with 1.4 million in the third quarter of 2024; and now I'll review the nine-month results. For the first nine months of 2025, total revenue increased 5.6% to 20.4 million, compared with 19.3 million in the first nine months of 2024. Direct patient care services segment revenue rose 36.5% year-over-year, reaching 10.7 million in the first nine months of 2025, versus 7.8 million in the first nine months of 2024. That big increase was driven mostly by revenue from the Rhode Island radiation therapy business and the newly launched Puebla, Mexico operations across the back half of 2024. Equipment leasing revenue dropped to 9.7 million, down from 11.5 million in the first nine months of 2024. Gamma knife revenue was down 4.2%, hitting 6.8 million over the first nine months of 2025, compared with 7.1 million in the same period of 2024. Gamma knife procedures came to 703 in that 2025 stretch, a decline from 831 in the matching 2024 stretch. Three customer contracts that ended beginning in the fourth quarter of 2024, plus softer PBRT volumes, were the chief reasons behind that decrease. PBRT revenue dropped 23%, to 5.7 million for the first nine months of 2025, versus 7.4 million a year before. Proton therapy fractions in Q3 2025 totaled 3,095, an 18% decline from the 3,764 fractions logged in the first nine months of 2024. Ordinary cyclical variation was the leading factor in that decline. Linac, or linear accelerator, system revenue hit 9.7 million in the first nine months of 2025, climbing from 4.8 million in the first nine months of 2024, because of the Rhode Island radiation therapy operations acquisition and the launch of Puebla, Mexico operations. Gross margins in the first nine months of 2025 rose 20.4%, to $4.2 million, against $6 million in the first nine months of 2024. This gross margin drop reflects lower volumes and increased operating costs tied to the shift toward direct patient services, which generate slimmer margins than the leasing segment. Operating loss in the first nine months of 2025 was $2.2 million, versus a loss of $975,000 in the first nine months of 2024. Net loss attributable to American Shared Hospital Services in the first nine months of 2025 was $922,000, or 14 cents per diluted share, compared with net income of $3.5 million, or 54 cents per diluted share, in the first nine months of 2024; the primary cause was the $3.9 million bargain purchase gain from the Rhode Island acquisition plus net income generated by the Rhode Island facilities acquired. Adjusted EBITDA, our non-GAAP financial measure, came to 4.6 million for the first nine months of 2025, against $5.1 million in the first nine months of 2024. Now let's move on to our balance sheet. We entered Q3 2025 in a strong financial position, underpinned by our balance sheet. As of September 30, 2025, cash and cash equivalents, including restricted cash, came to $5.1 million, compared with $11 million at December 31, 2024. That decline reflects $7.5 million of capital expenditures for Peru, Bristol, Rhode Island, and Northwestchester locations. Shareholders' equity, including non-controlling interest, stood at $24.6 million, or $3.78 per outstanding share, against $25.2 million, or $3.92 per outstanding share, at December 31, 2024. Fully diluted weighted average common shares outstanding were $6,856,000 for Q3 2025 and $6,482,000 for Q3 2024. Also, $0.03 per share, $0.14 per diluted share, $0.54 per diluted share, $11.3 million, $5.3 million, and 6,632,000. That concludes the final part of our presentation. We appreciate everyone being here with us again. We're looking forward to talking about what lies ahead in the next few quarters, including results such as $0.03 per share, $0.14 per diluted share, $0.54 per diluted share, $11.3 million, $5.3 million, and 6,632,000. And right now, we'd like to give the call back to the operator so we can begin taking your questions.
Tony Kamin
analystThanks. Ray and Gary, nice work — it's genuinely heartening to watch the execution and the Rhode Island integration finally begin to pay off. As you mentioned, Ray, given the sort of long-range vision you've held, you can at last see clearly where this is headed. And too, I suppose, since your pipeline looks so robust with actual projects — and I'd bet there are additional projects, or more early-stage items, that you haven't discussed — my guess is that pipeline is robust. So the business is performing well. My issue, though, is that the shareholders aren't performing well. And I think the clearest way to sort of demonstrate that — and this is my worry — is that if I annualize, again, just for simplicity's sake, this quarter's EBITDA, it comes to roughly $8 million. This morning you arrived with a $13 million market cap, which works out to around one and a half times EBITDA to market cap, while I'd expect a company such as this to trade far more likely, conservatively, at a 6 — perhaps as much as a 12 — multiple. And even taking that low end, a 6 multiple of EBITDA to market cap, the shares would exceed 8. Sadly, they remain in the very low twos. So my question is: now that you've gotten the company moving, and I realize you've wanted to concentrate on that, isn't it time — and in the interest of every shareholder and every constituency of the company — to do somewhat more when it comes to investor outreach, attending conferences, and so on? And my final sort of remark on this is: I know, Ray, you've purchased a great deal of stock. It would be good to see the other board members make some meaningful purchases to show their alignment with the shareholders and their confidence in the company. I think many of the long-term shareholders truly believe in the company, and we want to see that stock begin to reflect what appears to be an extraordinarily undervalued situation. Thank you.
Gary Delanois
executiveRay, do you want to go ahead and begin with that?
Scott Frech
executiveOkay, absolutely. So Tony, we appreciate you coming back and being with us today. We're grateful for your question too. Yes, it's important to keep in mind that some debt exists on our books when you bring up a valuation of $8 per share. There is indeed some debt there. So we've gone to a number of investor conferences, and given what you're saying, it seems like we ought to be doing more of that. That point is well taken. My sense is that the management team has been heavily concentrated on cost efficiencies and operational efficiencies, on the basics and the fundamentals. We would prefer that our results speak for themselves, but at times that won't happen unless you've got a bullhorn at the investor conferences, if you will; so Tony, that's very much noted.
Tony Kamin
analystOkay, thanks very much.
Anthony Marches
analystHello there, and good morning to everyone. Once more, strong numbers. Ray, or anyone else who wants to weigh in, what I'd really like to hear is your take on the reason our stock is sitting at a 52-week low while everything you're describing — the outlook, and even what came out today — looks entirely favorable. It feels like there's a real gap between where the market has us and what all of you are telling us. So I'm attempting to figure out how you'd explain that situation. What's the reason folks are unwilling to — well, "acknowledge" isn't quite the word I want — but what's the reason folks won't factor in the things you've been accomplishing compared with how the market values us?
Scott Frech
executiveYes. My sense is a big part of this comes down to how thin the trading volume is for us, plus the very limited exposure we have. That sort of ties back to what Tony asked at the beginning regarding building that exposure up. And certainly, I may turn to you for your views and input on this topic, since you're our investor relations firm. We've experimented with a handful of approaches here and there. What comes through very clearly and forcefully to me is that additional outreach is something we should be pursuing.
Anthony Marches
analystYes. Thanks, Ray; and yeah, I share those sentiments too, Tony. I believe spreading the narrative, communicating it more frequently, will certainly assist in boosting visibility for the entire company. I'll also second what Ray said. Nailing down the basics, at times it requires multiple consecutive quarters. As you can see, the past three quarters in succession have demonstrated improvement quarter over quarter. So it does require some time for that to appear on the radar. Management has kept their heads down well, concentrated on the company's operations. And I believe right now is an opportune moment for them to be out there and elevating that visibility too.
Gary Delanois
executiveThank you, operator, and thank you, Tony and Anthony, for your inquiries. We will consider them, and thank you. And thank you everyone for being with us today. We're at a pivotal moment as we carry out our expansion plan with significant business development prospects in our pipeline. We possess the correct team and the groundwork established and are intensely dedicated to generating robust momentum as our growth approach solidifies for the long haul; we anticipate providing you updates on our advancement as we propel additional top-line growth, profitability, and lasting success. As usual, should you have any inquiries, please feel free to contact us. And thank you for attending today, and take care. Thank you, operator.
Operator
operatorThat brings this call to a close. We appreciate your joining us for today's presentation. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.